Last reviewed · How we verify
Trivalent Inactivated Vaccine
Trivalent Inactivated Vaccine is a Inactivated vaccine Biologic drug developed by McMaster University. It is currently FDA-approved for Seasonal influenza prevention in adults and children. Also known as: VAXIGRIP by Sanofi Pasteur.
A trivalent inactivated influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus, providing protection against seasonal flu infection.
A trivalent inactivated influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus, providing protection against seasonal flu infection. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Trivalent Inactivated Vaccine |
|---|---|
| Also known as | VAXIGRIP by Sanofi Pasteur |
| Sponsor | McMaster University |
| Drug class | Inactivated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles or viral antigens representing three circulating strains (typically two A subtypes and one B lineage). When administered, these antigens trigger both humoral and cellular immune responses, leading to the production of neutralizing antibodies and memory B cells that recognize and neutralize the corresponding live virus upon natural exposure.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness, redness, or swelling
- Myalgia (muscle aches)
- Headache
- Low-grade fever
- Fatigue
Key clinical trials
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age (PHASE3)
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (PHASE3)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
- A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision (EARLY_PHASE1)
- Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children . (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trivalent Inactivated Vaccine CI brief — competitive landscape report
- Trivalent Inactivated Vaccine updates RSS · CI watch RSS
- McMaster University portfolio CI
Frequently asked questions about Trivalent Inactivated Vaccine
What is Trivalent Inactivated Vaccine?
How does Trivalent Inactivated Vaccine work?
What is Trivalent Inactivated Vaccine used for?
Who makes Trivalent Inactivated Vaccine?
Is Trivalent Inactivated Vaccine also known as anything else?
What drug class is Trivalent Inactivated Vaccine in?
What development phase is Trivalent Inactivated Vaccine in?
What are the side effects of Trivalent Inactivated Vaccine?
Related
- Drug class: All Inactivated vaccine drugs
- Manufacturer: McMaster University — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Seasonal influenza prevention in adults and children
- Also known as: VAXIGRIP by Sanofi Pasteur
- Compare: Trivalent Inactivated Vaccine vs similar drugs
- Pricing: Trivalent Inactivated Vaccine cost, discount & access